It’s not every day you check your voice mail to learn, that you are being...
If we’re treating pets for cancer, could we uncover new information that could help human patients? The answer, CSU veterinarians say, is “yes".
Vice President Joe Biden spoke today at the 2016 gathering of the American Society of Clinical Oncology (ASCO) in Chicago, pushing for greater sharing of data and a team approach to cancer science and care.
CU Cancer Center presented at ASCO 2016 finds that in Colorado patients over 50, the rate of CRC is falling at 2.5 percent per year while the rate of CRC in patients under 50 is rising at 0.8 percent per year. The increase in incidence appeared to be driven mostly by an increase in late-stage CRC in the under-50 population with an increase of 2.4 percent per year from 2003 through 2013.
Hispanic white and non-Hispanic black cancer patients between ages 15 and 29 may be more likely than same-aged white patients to die of their disease, according to a CU Cancer Center study presented at ASCO 2016.
Younger colorectal cancer patients are more likely to have alterations in genes involved in what is known as the Wnt signaling pathway, a system of communication that drives the growth, survival and proliferation of cancer stem cells.
Paul Bunn, Jr., MD, FASCO, has been named the 2016 David A. Karnofsky Memorial Award and Lecture recipient, a prestigious award presented at the American Society of Clinical Oncology’s (ASCO) Annual Meeting.
Friends of Colorado State University’s Flint Animal Cancer Center, a University of Colorado Cancer Center partner, recently gathered for the fifth annual One Cure fundraising dinner.
For First Time, Colorado Directly Funds Cancer Research
May 4, 2016 · Comments Off on For First Time, Colorado Directly Funds Cancer Research
Colorado Gov. John Hickenlooper signed a bill giving approximately $1.7 million annually to University of Colorado Cancer Center for cancer research.
June 29, 2016 · No comments
Study demonstrates a novel method for sorting passenger from driver alterations, and uses this method to pinpoint a new driver and potential therapeutic target in cancer progression, GON4L.